AGPAT3

Across TCGA pan-cancer cohorts, AGPAT3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AGPAT3 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AGPAT3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AGPAT3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where AGPAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.774	0.527	.002	35	view →
LUAD	DFS	Tertile	All	0.311	0.825	.001	15	view →
LSCC	OS	Median	II,III,IV	0.598	0.922	.004	10	view →
OV	DFS	Median	All	0.644	0.907	.032	4	view →
GBM	DFS	Tertile	All	0.482	0.288	.034	4	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AGPAT3–HNSC (DFS)

Open the HNSC breakdown →